Equities analysts predict that West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) will post sales of $758.33 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for West Pharmaceutical Services’ earnings, with the highest sales estimate coming in at $768.30 million and the lowest estimate coming in at $751.70 million. West Pharmaceutical Services reported sales of $723.60 million during the same quarter last year, which indicates a positive year-over-year growth rate of 4.8%. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that West Pharmaceutical Services will report full year sales of $3.06 billion for the current financial year, with estimates ranging from $3.05 billion to $3.06 billion. For the next fiscal year, analysts anticipate that the company will report sales of $3.31 billion, with estimates ranging from $3.21 billion to $3.40 billion. Zacks’ sales averages are a mean average based on a survey of research firms that follow West Pharmaceutical Services.
West Pharmaceutical Services (NYSE:WST – Get Rating) last released its quarterly earnings results on Thursday, April 28th. The medical instruments supplier reported $2.30 EPS for the quarter, topping the consensus estimate of $2.18 by $0.12. West Pharmaceutical Services had a return on equity of 30.33% and a net margin of 23.76%. The business had revenue of $720.00 million for the quarter, compared to analysts’ expectations of $720.92 million. During the same quarter in the previous year, the firm posted $2.05 earnings per share. The company’s revenue was up 7.4% compared to the same quarter last year.
West Pharmaceutical Services stock traded up $8.98 during midday trading on Wednesday, hitting $304.97. The stock had a trading volume of 310,223 shares, compared to its average volume of 502,738. The company has a current ratio of 2.89, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The stock has a market cap of $22.59 billion, a P/E ratio of 33.89, a P/E/G ratio of 3.00 and a beta of 1.17. West Pharmaceutical Services has a 12 month low of $288.12 and a 12 month high of $475.35. The business has a fifty day moving average price of $369.66 and a 200 day moving average price of $398.55.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 3rd. Shareholders of record on Wednesday, July 20th will be given a $0.18 dividend. The ex-dividend date is Tuesday, July 19th. This represents a $0.72 dividend on an annualized basis and a yield of 0.24%. West Pharmaceutical Services’s dividend payout ratio (DPR) is 8.00%.
In other West Pharmaceutical Services news, VP Quintin J. Lai sold 8,016 shares of the company’s stock in a transaction that occurred on Monday, March 14th. The stock was sold at an average price of $371.69, for a total value of $2,979,467.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.60% of the company’s stock.
Several large investors have recently made changes to their positions in WST. BlackRock Inc. lifted its position in shares of West Pharmaceutical Services by 8.9% during the 4th quarter. BlackRock Inc. now owns 8,094,288 shares of the medical instruments supplier’s stock valued at $3,796,302,000 after acquiring an additional 664,275 shares during the last quarter. Norges Bank acquired a new stake in shares of West Pharmaceutical Services during the 4th quarter valued at $307,506,000. Invesco Ltd. lifted its position in shares of West Pharmaceutical Services by 14.0% during the 3rd quarter. Invesco Ltd. now owns 1,260,099 shares of the medical instruments supplier’s stock valued at $534,963,000 after acquiring an additional 154,534 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of West Pharmaceutical Services by 42.3% in the third quarter. Arrowstreet Capital Limited Partnership now owns 515,148 shares of the medical instruments supplier’s stock valued at $218,701,000 after purchasing an additional 153,180 shares in the last quarter. Finally, Brown Advisory Inc. boosted its position in shares of West Pharmaceutical Services by 8.5% in the fourth quarter. Brown Advisory Inc. now owns 1,338,591 shares of the medical instruments supplier’s stock worth $627,811,000 after buying an additional 105,397 shares during the period. Institutional investors own 93.25% of the company’s stock.
West Pharmaceutical Services Company Profile (Get Rating)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
- Get a free copy of the StockNews.com research report on West Pharmaceutical Services (WST)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.